Eva Berner, new Chief People Officer, and Jörg Schulze, new Chief Commercial Officer for Abacus Medicine Pharma Services, are joining the Chief Executive Management Team.
On September 1st 2025, Abacus Medicine Group will welcome two new members to the Chief
Executive Management Team: Eva Berner, new Chief People Officer, and Jörg Schulze, new Chief Commercial Officer for Abacus Medicine Pharma Services, the business division that provides end-to-end commercialisation solutions for specialty and rare disease medicines.
“I am proud and happy to welcome Eva and Jörg. They join us at a pivotal moment where we are investing in continued growth with a strong focus on our people. Eva and Jörg are industry experts who will bring tremendous value to the Abacus Medicine Group,” says CEO Flemming Wagner.
Eva Berner has extensive experience in People & Culture leadership, having previously held senior roles at Teradyne, Orifarm and ISS. Most recently Eva has been with law firm Focus Advokater, where she has overseen strategy, organizational development and all staff functions.
Eva Berner is a Danish national and holds a master’s degree in business administration and commercial law from Aarhus University.
Jörg Schulze most recently served as General Manager for the Nordic Cluster in the multinational pharma company Bristol-Myers Squibb (BMS). During his 12 years with BMS, he led several launches of innovative specialty care therapies, transforming the Nordic Cluster into a high-performing region.
A German national, Jörg Schulze holds a Ph.D. in Molecular Biology and Biochemistry from Harvard Medical School and the University of Cologne.